File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer

TitleEmerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer
Authors
Keywordsbreast cancer
cyclin-dependent kinase inhibitor
endocrine therapy
treatment resistance
Issue Date2018
Citation
Asia-Pacific Journal of Clinical Oncology, 2018, v. 14, p. 12-21 How to Cite?
AbstractCyclin-dependent kinase (CDK4/6) inhibitors in combination with endocrine therapy are currently the optimal first line treatment for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) non-amplified metastatic breast cancer (MBC). However, not all patients benefit from this treatment and all patients will inevitably progress. Identifying therapeutic strategies in this setting is therefore of immediate clinical importance. We present an overview of the mechanisms of resistance to CDK4/6 inhibitors and review potential biomarkers that may guide therapy selection. We also discuss the use of CDK4/6 inhibitors in the context of non-HR-positive/HER2-non-amplified breast cancer and in combination with therapies other than endocrine therapy.
Persistent Identifierhttp://hdl.handle.net/10722/326478
ISSN
2023 Impact Factor: 1.4
2023 SCImago Journal Rankings: 0.531
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLim, Elgene-
dc.contributor.authorBeith, Jane-
dc.contributor.authorBoyle, Frances-
dc.contributor.authorde Boer, Richard-
dc.contributor.authorHui, Rina-
dc.contributor.authorMcCarthy, Nicole-
dc.contributor.authorRedfern, Andrew-
dc.contributor.authorWade, Theresa-
dc.contributor.authorWoodward, Natasha-
dc.date.accessioned2023-03-10T02:19:34Z-
dc.date.available2023-03-10T02:19:34Z-
dc.date.issued2018-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, 2018, v. 14, p. 12-21-
dc.identifier.issn1743-7555-
dc.identifier.urihttp://hdl.handle.net/10722/326478-
dc.description.abstractCyclin-dependent kinase (CDK4/6) inhibitors in combination with endocrine therapy are currently the optimal first line treatment for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) non-amplified metastatic breast cancer (MBC). However, not all patients benefit from this treatment and all patients will inevitably progress. Identifying therapeutic strategies in this setting is therefore of immediate clinical importance. We present an overview of the mechanisms of resistance to CDK4/6 inhibitors and review potential biomarkers that may guide therapy selection. We also discuss the use of CDK4/6 inhibitors in the context of non-HR-positive/HER2-non-amplified breast cancer and in combination with therapies other than endocrine therapy.-
dc.languageeng-
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology-
dc.subjectbreast cancer-
dc.subjectcyclin-dependent kinase inhibitor-
dc.subjectendocrine therapy-
dc.subjecttreatment resistance-
dc.titleEmerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/ajco.13065-
dc.identifier.pmid30288929-
dc.identifier.scopuseid_2-s2.0-85054291402-
dc.identifier.volume14-
dc.identifier.spage12-
dc.identifier.epage21-
dc.identifier.eissn1743-7563-
dc.identifier.isiWOS:000446426100002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats